In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Centocor to develop 3-D Pharmaceuticals' thrombin inhibitors

Executive Summary

J&J's biotech subsidiary Centocor has acquired from 3-Dimensional Pharmaceuticals (genomics technology for drug discovery) its program in orally active direct thrombin inhibition, including the lead anticoagulant compound, 3DP-4815, which is in Phase I.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register